Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456791 | 0.98 | HRH3 (0.59) | HRH3HRH1SCDSCN9APARP1 | |
| SCHEMBL5464213 | 0.89 | HRH3 (0.50) | HRH3HRH1SMO | |
| SCHEMBL5470110 | 0.89 | HRH3 (0.48) | HRH3HRH1 | |
| SCHEMBL5468020 | 0.88 | HRH3 (0.47) | HRH3HRH1 | |
| SCHEMBL5453310 | 0.87 | HRH3 (0.48) | HRH3HRH1SMO | |
| SCHEMBL5466072 | 0.87 | HRH3 (0.64) | HRH3HRH1SCN9A | |
| SCHEMBL5462217 | 0.87 | HRH3 (0.64) | HRH3HRH1SCDPARP1 | |
| SCHEMBL5459907 | 0.87 | HRH3 (0.46) | HRH3HRH1 | |
| SCHEMBL5450896 | 0.85 | HRH3 (0.64) | HRH3HRH1SCN9A | |
| SCHEMBL4774177 | 0.79 | HRH3 (0.69) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885HRH1 101/4885SCD 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.